Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALX Oncology Holdings

1.61
+0.230016.67%
Volume:456.82K
Turnover:713.58K
Market Cap:87.29M
PE:-0.80
High:1.62
Open:1.39
Low:1.38
Close:1.38
52wk High:2.27
52wk Low:0.4040
Shares:54.22M
Float Shares:28.99M
Volume Ratio:1.84
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0202
EPS(LYR):-2.5846
ROE:-104.21%
ROA:-47.78%
PB:1.36
PE(LYR):-0.62

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Yesterday

ALX Oncology Holdings (ALXO) Gets a Buy from Jefferies

TIPRANKS
·
Nov 13

ALX Oncology Holdings Inc : Jefferies Initiates Coverage With Buy Rating; Price Target $4

THOMSON REUTERS
·
Nov 13

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR)

TIPRANKS
·
Nov 10

ALX Oncology Holdings Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 07

ALX Oncology Q3 net loss narrows as R&D costs drop

Reuters
·
Nov 07

ALX Oncology Names Barbara Klencke as Chief Medical Officer

Reuters
·
Nov 07

ALX Oncology Holdings Q3 Adj. EPS $(0.36) Beats $(0.37) Estimate

Benzinga
·
Nov 07

BRIEF-ALX Oncology Q3 Basic EPS USD -0.41

Reuters
·
Nov 07

ALX Oncology Holdings Inc - Phase 2 Aspen-09-Breast Cancer Trial Remains on Track for Fpi in Q4 2025

THOMSON REUTERS
·
Nov 07

ALX Oncology Q3 Income From Operations USD -22.532 Million

THOMSON REUTERS
·
Nov 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 07

ALX Oncology Holdings Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
Nov 05

ALX Oncology Holdings Inc. to Report Third Quarter 2025 Financial Results

Reuters
·
Oct 30

ALX presents preclinical data, Phase 1 trial-in-progress for ALX2004

TIPRANKS
·
Oct 24

ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004

Reuters
·
Oct 24

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of Alx2004, a Novel Egfr-Targeted ADC, at 2025 Aacr-Nci-Eortc Conference

THOMSON REUTERS
·
Oct 24

ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker

Reuters
·
Oct 03

3 Promising Penny Stocks With Market Caps Under $700M

Simply Wall St.
·
Sep 26

ALX Oncology Appoints Dr. Barbara Klencke as Interim Chief Medical Officer, Succeeding Dr. Alan Sandler

Reuters
·
Sep 12